Shopping Cart
- Remove All
Your shopping cart is currently empty
BT2
Catalog No. T14834Cas No. 34576-94-8
BT2, a BCKDC kinase (BDK) inhibitor, exhibits an IC50 of 3.19 μM and functions as a potent, selective Mcl-1 inhibitor with a Ki value of 59 μM. Its interaction with BDK induces helix movements in the N-terminal domain, leading to BDK's dissociation from the branched-chain α-ketoacid dehydrogenase complex (BCKDC).
BT2
Catalog No. T14834Cas No. 34576-94-8
BT2, a BCKDC kinase (BDK) inhibitor, exhibits an IC50 of 3.19 μM and functions as a potent, selective Mcl-1 inhibitor with a Ki value of 59 μM. Its interaction with BDK induces helix movements in the N-terminal domain, leading to BDK's dissociation from the branched-chain α-ketoacid dehydrogenase complex (BCKDC).
| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 10 mg | $39 | In Stock | |
| 25 mg | $58 | In Stock | |
| 50 mg | $72 | In Stock | |
| 100 mg | $105 | In Stock | |
| 500 mg | $256 | In Stock | |
| 1 mL x 10 mM (in DMSO) | $38 | In Stock |
Bulk & Custom
Add to Cart
Questions
View MoreInhibitors Related to "BT2"
Navitoclax
Cited
ABT-263
T2101923564-51-6
Navitoclax (ABT-263) is a potent oral Bcl-2 inhibitor that binds to Bcl-xL, Bcl-2, and Bcl-w proteins (Ki<1 nM), demonstrating antitumor activity and inducing apoptosis.
- $41
Size
QTY
CitedVenetoclax Cited
GDC-0199, ABT-199, ABT199, ABT 199
T21191257044-40-8
Venetoclax (ABT-199) is a Bcl-2 inhibitor (Ki<0.01 nM) with potent, selective, and orally active properties. Venetoclax has a 3-order-of-magnitude lower affinity for Bcl-xL and Bcl-W (Kis=48/245 nM). Venetoclax induces autophagy and apoptosis.
- $48
Size
QTY
Cited(S)-(+)-Ibuprofen
Dexibuprofen, (S)-Ibuprofen
T044851146-56-6
(S)-(+)-Ibuprofen (Dexibuprofen) , is a non-steroidal anti-inflammatory drug (NSAID), inhibiting cyclooxygenase (COX).
- $35
Size
QTY
Lisaftoclax
Bcl-2/Bcl-xl inhibitor 1, APG-2575
T104832180923-05-9
Lisaftoclax (Bcl-2/Bcl-xl inhibitor 1) is an oral dual inhibitor of Bcl-2 and Bcl-xl, with IC50 values of 2 nM and 5.9 nM for Bcl-2 and Bcl-xl, respectively. Lisaftoclax is used to treat chronic lymphocytic leukemia (CLL) by inhibiting the action of the BCL-2 protein, which promotes the death of leukemia cells.
- $187
Size
QTY
Triacetylresveratrol
Acetyl-trans-resveratrol
T566842206-94-0
Triacetylresveratrol (Acetyl-trans-resveratrol) has anti-cancer activity,it inhibits the phosphorylation of STAT3 and NFκB, down-regulates Mcl-1, and up-regulates Bim and Puma in pancreatic cancer cells.
- $68
Size
QTY
Gossypol
Pogosin, NSC 56817, BL 193
T6518303-45-7
Gossypol (BL 193) Acetate is a polyphenolic aldehyde that permeates cells and acts as an inhibitor for several dehydrogenase enzymes.
- $35
Size
QTY
Diphenyl disulfide
Phenyl disulfide
T37518882-33-7
Diphenyl disulfide (Phenyl disulfide) shows anticancer activity in breast cancer cell lines.Diphenyl disulfide induces and enhances apoptosis in breast cancer cells through Bax protein hydrolysis activation and concomitant autophagy.Diphenyl disulfide inhibits cell proliferation and viability and reduces colony formation in a dose-dependent manner. Diphenyl disulfide can be used to treat breast cancer.
- $30
Size
QTY
Gossypol (acetic acid) Cited
Pogosin, Gossypol acetic acid, AT101, (±)-Gossypol-acetic acid
T273012542-36-8
Gossypol acetic acid (AT101), a polyphenolic compound isolated from cottonseeds, binds with Bcl-2, Bcl-xL, Mcl-1, and does not inhibit BIR3 domain and BID.
- $30
Size
QTY
Cited(E)-Ferulic acid
trans-Ferulic acid, (E)-Coniferic acid
T5679537-98-4
(E)-Ferulic acid ((E)-Coniferic acid) causes the phosphorylation of β-catenin, resulting in proteasomal degradation of β-catenin and increases the expression of pro-apoptotic factor Bax and decreases the expression of pro-survival factor survivin.t(E)-Ferulic acid exert both anti-proliferation and anti-migration effects in the human lung cancer cell line H1299.
- $34
Size
QTY
Select Batch
Purity:99.86%
Contact us for more batch information
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.Product Introduction
Bioactivity
Chemical Properties
| Description | BT2, a BCKDC kinase (BDK) inhibitor, exhibits an IC50 of 3.19 μM and functions as a potent, selective Mcl-1 inhibitor with a Ki value of 59 μM. Its interaction with BDK induces helix movements in the N-terminal domain, leading to BDK's dissociation from the branched-chain α-ketoacid dehydrogenase complex (BCKDC). |
| Targets&IC50 | BDK:3.19 μM (IC50), MCL1:59 μM (Ki) |
| In vivo | BT2 treatment reduces the protein levels of BDK in kidneys and heart. The -fold activation of BCKDC activity in the above tissues correlates with decreased phosphorylation in heart, muscle, and kidney after the long term BT2 treatment. BT2 (20 mg/kg/day; i.p.; daily; for 7 days; C57BL/6J male mice) treatment robustly enhances BCKDC activity in the heart (12.3-fold) compared with the vehicle-treated animals. Less activation is obtained in muscle and kidney at 3.6- and 3.8-fold, respectively [1]. |
| Molecular Weight | 247.1 |
| Formula | C9H4Cl2O2S |
| Cas No. | 34576-94-8 |
Storage & Solubility Information
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 83.33 mg/mL (337.23 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . A total of 10 animals were administered, and the formula you used is 5% 
DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.Preparation method for in vivo formula: Take 50 μL DMSO main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarify
main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarifyFor Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: buy BT2 | purchase BT2 | BT2 cost | order BT2 | BT2 chemical structure | BT2 in vivo | BT2 formula | BT2 molecular weight
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.